Literature DB >> 12846919

A clinical model of dermal wound angiogenesis.

A Craig Lockhart1, Rod D Braun, Daohai Yu, Joel R Ross, Mark W Dewhirst, Bruce Klitzman, Fan Yuan, James M Grichnik, Alan D Proia, Delina A Conway, Gretchen Mann, Herbert I Hurwitz.   

Abstract

Full-thickness dermal biopsies were performed in healthy volunteers to establish the range of angiogenic responses in wound healing in a normal population. Four-millimeter punch biopsies were made in the forearms of 15 healthy volunteers. Each wound was evaluated microscopically 4-5 times per week for 2 weeks. A semiquantitative wound scoring system to evaluate the neovasculature at the wound periphery was investigated. A vascular score was calculated for each wound at each observation. Two independent observers analyzed the microscopic wound images using the scoring system. At the end of the 14-day period, repeat biopsies were performed on some of the volunteers, and the granulation tissue was stained with anti-CD31. The Kaplan-Meier method was used to estimate the distribution of the time to reach predetermined target average vascular scores. A mixed-effects regression model indicated that time, age, and observer were predictors for the average vascular score outcome. The pattern and time course for wound neovascularization was highly reproducible in this group of healthy volunteers, and the assay was feasible and well tolerated. This wound angiogenesis model may be useful for monitoring the effects of antiangiogenic agents on normal wound neovascularization.

Entities:  

Mesh:

Year:  2003        PMID: 12846919     DOI: 10.1046/j.1524-475x.2003.11411.x

Source DB:  PubMed          Journal:  Wound Repair Regen        ISSN: 1067-1927            Impact factor:   3.617


  8 in total

1.  A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors.

Authors:  Elizabeth Dugan; Roxanne Truax; Kellen L Meadows; Andrew B Nixon; William P Petros; Justin Favaro; Nishan H Fernando; Michael A Morse; Gerard C Blobe; Herbert I Hurwitz
Journal:  Anticancer Res       Date:  2010-04       Impact factor: 2.480

2.  Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing.

Authors:  Jingquan Jia; Andrew E Dellinger; Eric S Weiss; Anuradha Bulusu; Christel Rushing; Haiyan Li; Leigh A Howard; Neal Kaplan; Herbert Pang; Herbert I Hurwitz; Andrew B Nixon
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

3.  Biomechanical regulation of blood vessel growth during tissue vascularization.

Authors:  Witold W Kilarski; Branka Samolov; Ludvig Petersson; Anders Kvanta; Pär Gerwins
Journal:  Nat Med       Date:  2009-06       Impact factor: 53.440

Review 4.  Understanding the Hawthorne effect in wound research-A scoping review.

Authors:  Van Nb Nguyen; Charne Miller; Janine Sunderland; William McGuiness
Journal:  Int Wound J       Date:  2018-08-22       Impact factor: 3.315

5.  A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors.

Authors:  Niharika B Mettu; Donna Niedzwiecki; Christel Rushing; Andrew B Nixon; Jingquan Jia; Sherri Haley; Wanda Honeycutt; Herbert Hurwitz; Johanna C Bendell; Hope Uronis
Journal:  Cancer Chemother Pharmacol       Date:  2019-03-20       Impact factor: 3.333

6.  A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer.

Authors:  Gordana Vlahovic; Kellen L Meadows; Ace J Hatch; Jingquan Jia; Andrew B Nixon; Hope E Uronis; Michael A Morse; M Angelica Selim; Jeffrey Crawford; Richard F Riedel; S Yousuf Zafar; Leigh A Howard; Margot O'Neill; Jennifer J Meadows; Sherri T Haley; Christy C Arrowood; Christel Rushing; Herbert Pang; Herbert I Hurwitz
Journal:  Oncologist       Date:  2018-03-23

Review 7.  Mechanical Forces in Tumor Angiogenesis.

Authors:  Matthew R Zanotelli; Cynthia A Reinhart-King
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

8.  A phase I study of ABT-510 plus bevacizumab in advanced solid tumors.

Authors:  Hope E Uronis; Stephanie M Cushman; Johanna C Bendell; Gerard C Blobe; Michael A Morse; Andrew B Nixon; Andrew Dellinger; Mark D Starr; Haiyan Li; Kellen Meadows; Jon Gockerman; Herbert Pang; Herbert I Hurwitz
Journal:  Cancer Med       Date:  2013-03-21       Impact factor: 4.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.